ABOUT THIS PODCAST
This podcast evaluates the roles of intravenously (IV)administered vancomycin and IV or orally (PO) administered linezolid for the empiric management of suspected or confirmed infections caused by methicillin-resistant Staphylococcus aureus (MRSA). We discuss and compare the positive and negative attributes of each drug and how those impact their places in the therapeutic management of MRSA infections.
SHOW NOTES
- Accuracy of vancomycin AUC values estimated with trough-only data in a veteran population
- Comparison of Open-Access, Trough-Only Online Calculators Versus Trapezoidal Method for Calculation of Vancomycin Area Under the Curve (AUC)
- Expert consensus statement on therapeutic drug monitoring and individualization of linezolid
- Linezolid-associated serotonin toxicity: a systematic review
- Association of Linezolid With Risk of Serotonin Syndrome in Patients Receiving Antidepressants
SPEAKERS
- Kyle Piscitello, PharmD, BCIDP
Lead Antimicrobial Stewardship/Infectious Diseases Pharmacy Specialist, Ascension Wisconsin - Cara Slaton, PharmD, BCIDP
Clinical Pharmacy Speialist, Infectious Diseases and Antimicrobial Stewardship, Orlando Health - Natalie Carleton, PharmD, BCPS
Pharmacy Manager of Clinical Initiatives and Drug Utilization, Ascension Wisconsin
